Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Incruse Ellipta is a prescription long-acting anticholinergic inhalation medicine containing umeclidinium. It is indicated for maintenance treatment of chronic obstructive pulmonary disease. Each actuation contains 62.5 mcg of umeclidinium.
read more about incruse ellipta ...Umeclidinium is a long-acting muscarinic antagonist. It blocks M3 muscarinic receptors in airway smooth muscle, leading to bronchodilation. This helps keep airways more open during long-term COPD treatment.
Incruse Ellipta is used for long-term maintenance treatment of chronic obstructive pulmonary disease. It is not used to relieve sudden breathing symptoms and does not replace a rescue inhaler. Safety and efficacy are not established in pediatric patients.
The recommended dose is one oral inhalation of 62.5 mcg once daily at the same time each day. The inhaler is not used more than once in 24 hours. No dose adjustment is required for older adults, kidney impairment, or moderate liver impairment.
Incruse Ellipta can cause paradoxical bronchospasm and serious hypersensitivity reactions. It can also worsen narrow-angle glaucoma or urinary retention. Severe milk protein allergy is a contraindication, and use with other anticholinergic medicines is avoided due to additive adverse effects.
Incruse Ellipta is used for maintenance treatment of chronic obstructive pulmonary disease.
The recommended dose is one inhalation of 62.5 mcg once daily.
No. It is not used for sudden breathing symptoms.
Yes. It can worsen narrow-angle glaucoma and urinary retention.
A Randomized Blinded Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 mcg Compared With Tiotropium 18 mcg in Patients With COPD. https://pubmed.ncbi.nlm.nih.gov/27103795/. Date Accessed October 2, 2026.
DailyMed - INCRUSE ELLIPTA - umeclidinium inhalation powder. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3. Date Accessed October 2, 2026.
Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients With COPD. https://pubmed.ncbi.nlm.nih.gov/32368027/. Date Accessed October 2, 2026.
INCRUSE ELLIPTA Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205382s006lbl.pdf. Date Accessed October 2, 2026.
Umeclidinium Oral Inhalation - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a614024.html. Date Accessed October 2, 2026.